Comparative Study of CD26 as a Th1-Like and CD30 as a Potential Th2-Like Operational Marker in Leprosy

  • Ulrike Seitzer
  • Dagmar Scheel-Toellner
  • Margrit Hahn
  • Gesine Heinemann
  • Taila Mattem
  • Hans-Dieter Flad
  • Johannes Gerdes
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 421)

Abstract

In the last years we have been able to establish CD26 as an operational marker for a human Thl -like reaction in various granulomatous diseases. Recently, CD30 was described as a marker for a Th2-type reaction, where CD30 is preferentially expressed and its soluble form released by human T cell clones producing Th2-type cytokines. To evaluate the possibility of CD30 as an eventual operational marker for a human Th2-like reaction in vivo, we performed immunohistological stainings on frozen sections of skin biopsies from patients with lepromatous and tuberculoid leprosy. A maximum of three to four CD30-positive cells was found per section, and there was no difference in the accumulation of CD30-positive cells between the tuberculoid and the lepromatous form of leprosy. With respect to CD26-positive cells, a high number was found in tuberculoid leprosy in contrast to a greatly reduced expression of CD26 in lepromatous leprosy. We conclude that, while CD26 was confirmed as an operational marker for a Thl-like reaction in leprosy, CD30 does not represent an operational Th2 marker in this disease.

Keywords

Lepromatous Leprosy Immunohistological Staining Operational Marker Tuberculoid Leprosy Leukocyte Biology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Romagnani S (1991) Human Th I and Th2 subsets: doubt no more. Immunology Today 12: 256–257.PubMedCrossRefGoogle Scholar
  2. 2.
    Mosman TR, Cerwinski H, bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone I. Definition according to profiles of lymphkine activities and secreted proteins. The Journal of Immunology 136: 2348–2357.Google Scholar
  3. 3.
    Modlin RL (1994) ThI-Th2 paradigm: insights from leprosy. Journal of Investigative Dermatology 102: 828–832.PubMedCrossRefGoogle Scholar
  4. 4.
    Scheel-Toellner D, Richter E, Toellner K-M, Reiling N, Wacker H-H, Flad H-D. Gerdes J (1995) CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-y. Laboratory Investigation 73: 685–690.PubMedGoogle Scholar
  5. Mattern T, Ulmer AJ. Scheel-Toellner D, Flad H-D (1995) CD26 as a functional marker of TH 1 lymphocytes. In “Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response” (ed. Fleischer B.) R.G. Landes Company, Austin, Texas, USA, 185–199.Google Scholar
  6. 6.
    Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G (1995) CD30 and type 2 T helper (Th2) responses. Journal of Leukocyte Biology 57: 726–730.PubMedGoogle Scholar
  7. 7.
    Ridley DS, Jopling WH (1966) Classification of leprosy according to immunity. A five group system. International Journal of Leprosy 34: 255–273.Google Scholar
  8. 8.
    Cordell JL, Fallini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase ( APAAP complexes ). Journal of Histochemistry and Cytochemistry 32: 219–229.Google Scholar
  9. 9.
    Scheel D, Richter E, Toellner K-M, Reiling N, Key G, Wacker H-H, Ulmer AJ, Flad H-D, Gerdes J (1995) Correlation of CD26 expression with Thl-like reactions in granulomatous diseases. In: Leucocyte Typing V “White Cell Differentiation Antigens” (SF Schlossmann, L Boumsell, W Gilks, JM Harlan, T Kishimoto, C Morimoto, J Ritz, S Shaw, R Silverstein, T Springer, TF Tedder, RF Todd, eds), Oxford University Press, Oxford, 1111–1114.Google Scholar
  10. 10.
    Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H (1989) Ber-H2: A new anti-K1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74: 1678–1689.PubMedGoogle Scholar
  11. 11.
    Collings LA, Poulter LW (1985) The involvement of dendritic cells in the cutaneous lesions associated with tuberculoid and lepromatous leprosy. Clinical and Experimental Immunology 62: 458–467.PubMedGoogle Scholar
  12. 12.
    Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299: 65–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Hamann D, Hilkens CMU, Grogan JL, Lens SMA, Kapsenberg ML, Yazdanbaksh M. van Lier RAW (1996) CD30 expression does not discriminate between human Th i–and Th2-type cells. The Journal of Immunology 156: 1387–1391.PubMedGoogle Scholar
  14. Bengtsson A, Johansson C, Linder MT. Hallden G, van der Ploeg I, Scheynius A (1995) Not only Th2 cells but also ThI and Tho cells express CD30 after activation. Journal of Leukocyte Biology 58:683–689.Google Scholar
  15. 15.
    Del Prete G, de Carli M, D’Elios MM, Daniel KC, Almerigogna F, Alderson M, Smith CA, Thomas E, Ro-magnani S (1995) CD30-mediated signaling promotes the development of human T helper type 2-like cells. Journal of Experimental Medicine 182: 1655–1661.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Ulrike Seitzer
    • 1
  • Dagmar Scheel-Toellner
    • 1
  • Margrit Hahn
    • 1
  • Gesine Heinemann
    • 1
  • Taila Mattem
    • 1
  • Hans-Dieter Flad
    • 1
  • Johannes Gerdes
    • 1
  1. 1.Department of Immunology and Cell Biology Division of Molecular ImmunologyForschungszentrum BorstelBorstelGermany

Personalised recommendations